About UsMembershipMarketplaceResourcesGlobal Business Atlas
Top AI CompaniesTop Blockchain Influencers & AuthorsTop Global Digital AgenciesBusinessabc Country IndexesTop Accelerators and Chambers of CommerceTop Public Companies by MarketcapBusinessabc Education IndexesTop Malaysian Companies
DirectoryCompaniesLeadersInvestorsUniversitiesOrganisations
Loading wiki page…

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More
Last Updated: 2026
Denali Therapeutics image

Denali Therapeutics

Rank#3900
Market Cap3.56B
CountryUnited States
Summary
History
Mission
Vision
References
Summaryarrow
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Historyarrow

Denali Therapeutics was founded in 2015 by world-renowned scientists and biotech leaders with a shared vision of reversing the course of devastating diseases by creating transformative medicines. The company combines scientific, medical and drug development expertise with a deep understanding of the genetic and molecular causes of disease, enabling the development of precision medicines designed to treat the underlying causes of neurologic disorders.

Missionarrow
Our mission is to discover and develop breakthrough medicines to extend and improve the lives of people with neurological diseases and to be a leader in advancing precision medicine.
Visionarrow
Our vision is to convert revolutionary discoveries into innovative and transformative therapies that change the lives of people with certain neurological disorders, especially Alzheimer’s disease and Parkinson’s disease.
Referencesarrow

https://in.investing.com/equities/denali-therapeutics

https://finance.yahoo.com/quote/DNLI/profile?p=DNLI

https://www.comparably.com/companies/denali-therapeutics/mission

https://www.crunchbase.com/organization/denali-therapeutics

https://sec.report/CIK/0001714899

https://companiesmarketcap.com/

https://www.denalitherapeutics.com

Share

Leadership team
D
Dr. Alexander O. Schuth M.D. (Co-Founder, CFO, COO & Sec.)
D
Dr. Ryan J. Watts Ph.D. (Co-Founder, Pres, CEO & Director)
D
Dr. Marc Tessier-Lavigne Ph.D. (Co-Founder, Chairman of Scientific Advisory Board & Independent Director)
Products / Services
Biotechnology, Genetics, Health Diagnostics, Therapeutics
Number of Employees
100 - 500
Address
San Francisco, California, United States
Established
2013-01-01
Company Registration
SEC CIK number: 0001714899
Revenue
100M - 500M
Traded as
DNLI
Website
https://www.denalitherapeutics.com
Social Media
linkedin
Last Updated: 2026
Logo

Businessabc provides digital business directory, digital blockchain AI certification, resources, and marketplace for businesses, organisations, and professionals.

Contacts

Email
Contact

Follow Us

Created Produced

Partner logo
Partner logo

Tech AI Media Platforms

Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo

Copyright 2026 © Businessabc powered by

Powered by ztudium group

DisclaimerPrivacy PolicyTerms of Service
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo